MULTITHERAPY AGAINST CANCER

摘要

The invention concerns a pharmaceutical composition for treating cancer characterized in that it comprises a combination of a PP2A methylating agent and an active principle selected among the group consisting of a phosphatase PP1 inhibitor, a histone diacetylase inhibitor, a direct or indirect pyruvate kinase activator, a PTEN agonist, a tyrosine kinase inhibitor, a Pl3 kinase inhibitor, a glucose competitor, a phosphoenol pyruvate carboxykinase inhibitor, a citrate synthase inhibitor and a latctate dehydrogenase inhibitor.